By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers ...
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...